The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it selected for negotiation.

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) appeared to offer better prevention of stroke and thromboembolic events ...

The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Like Eliquis, some saw increases of more than double, including: Trulicity (dulaglutide) for Type 2 diabetes, from $54.04 to $128.43 Xarelto (rivaroxaban) for blood clots, from $46.54 to $ 94.50 ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...